6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 29, 2019

Commission File Number: 001 - 38178

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Sydmarken 11
2860 Søborg (Copenhagen)
Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x            Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Zealand Pharma A/S or the Company, dated November 27, 2019, Zealand Pharma (“Zealand”) discloses information on transactions with the company’s shares and related securities by managers and persons/companies closely related to them, pursuant to the Danish Securities Trading Act, section 28a.

Furnished as Exhibits 99.2 to 99.5 are disclosure documents as referenced in the press release.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Zealand Pharma A/S
By:	/s/ Matthew Dallas
	Name:	Matthew Dallas
	Title:	Chief Financial Officer

Date: November 29, 2019

2

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated November 27, 2019
99.2	H. H. Bak — shares
99.3	H. H. Bak — warrants
99.4	R. S. Hansen — warrants
99.5	R. S. Hansen — shares

3

EX-99.1

Exhibit 99.1

Company announcement — No. 40 / 2019

Notification of managers and closely related parties’ transactions with Zealand Pharma shares in connection with employee warrant program

Copenhagen, November 27, 2019 — Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78) discloses information on transactions with the company’s shares and related securities by managers and persons/companies closely related to them.

With reference to the above, Zealand announces that it has received information on transactions for disclosure. Please see the attached files.

For further information, please contact:

Zealand Pharma Investor Relations

+45 50 60 38 00 investors@zealandpharma.com

Lani Pollworth Morvan, Investor Relations and Communication

lpm@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of innovative peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s current pipeline of internal product candidates focus on specialty gastrointestinal and metabolic diseases. Zealand’s portfolio also includes two clinical license collaborations with Boehringer Ingelheim and pre-clinical license collaboration with Alexion Pharmaceuticals.

Zealand is based in Copenhagen (Søborg), Denmark. For further information about the Company’s business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.

1

EX-99.2

Exhibit 99.2

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them Updated 5 March 2018 1. Details of the person discharging managerial responsibilities/person closely associated a) Name 2. Reason for the notification a) Position/status b) Initial notifica-tion/Amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-tion monitor a) Name b) LEI 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instru-ment Identification code b) Nature of the transaction c) Price(s) and volume(s) Price(s) Volume(s) d) Aggregated information -Aggregated volume -Price e) Date of the transaction f) Place of the transaction

EX-99.3

Exhibit 99.3

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them Updated 5 March 2018 1. Details of the person discharging managerial responsibilities/person closely associated a) Name 2. Reason for the notification a) Position/status b) Initial notifica-tion/Amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-tion monitor a) Name b) LEI 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instru-ment Identification code b) Nature of the transaction c) Price(s) and volume(s) Price(s) Volume(s) d) Aggregated information -Aggregated volume -Price e) Date of the transaction f) Place of the transaction

EX-99.4

Exhibit 99.4

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them Updated 5 March 2018 1. Details of the person discharging managerial responsibilities/person closely associated a) Name 2. Reason for the notification a) Position/status b) Initial notifica-tion/Amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-tion monitor a) Name b) LEI 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instru-ment Identification code b) Nature of the transaction c) Price(s) and volume(s) Price(s) Volume(s) d) Aggregated information -Aggregated volume -Price e) Date of the transaction f) Place of the transaction

EX-99.5

Exhibit 99.5

Template for notification and public disclosure of transactions by persons discharging manage-rial responsibilities and persons closely associated with them Updated 5 March 2018 1. Details of the person discharging managerial responsibilities/person closely associated a) Name 2. Reason for the notification a) Position/status b) Initial notifica-tion/Amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auc-tion monitor a) Name b) LEI 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instru-ment Identification code b) Nature of the transaction c) Price(s) and volume(s) Price(s) Volume(s) d) Aggregated information -Aggregated volume -Price e) Date of the transaction f) Place of the transaction